Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuaki Sagara

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
Breast Cancer (Tokyo, Japan)|July 22, 2019
Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer SocietyTakashi Hojo, Norikazu Masuda, Takayuki Iwamoto, et al.
International Journal of Clinical Oncology|January 22, 2026
Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trialHideo Shigematsu, Tomomi Fujisawa, Fumikata Hara, et al.
Breast Cancer (Tokyo, Japan)|December 29, 2025
Postoperative course and safety profile of the suture scaffold technique in breast-conserving surgery: a single-institution observational studyReiko Mitsueda, Yasuyo Ohi, Yukari Mochitomi, et al.
The Oncologist|December 15, 2020
Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast CancerYasuaki Sagara, Masanori Mori, Sena Yamamoto, et al.
Breast Cancer (Tokyo, Japan)|October 19, 2021
Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of JapanDaisuke Yotsumoto, Yasuaki Sagara, Hiraku Kumamaru, et al.
The Lancet. Oncology|May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studyKenji Tamura, Junji Tsurutani, Shunji Takahashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2020
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib StudyShanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2020
Reply to T.J.A. DekkerShanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Breast Cancer (Tokyo, Japan)|January 31, 2026
Efficacy and prognostic predictors of primary systemic therapy for de novo Stage IV breast cancer. Exploratory analysis of JCOG1017 PRIM-BCTadahiko Shien, Makoto Ishitobi, Keita Sasaki, et al.
Trials|May 9, 2020
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
Breast Cancer (Tokyo, Japan)|July 22, 2019
Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer SocietyTakashi Hojo, Norikazu Masuda, Takayuki Iwamoto, et al.
International Journal of Clinical Oncology|January 22, 2026
Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trialHideo Shigematsu, Tomomi Fujisawa, Fumikata Hara, et al.
Breast Cancer (Tokyo, Japan)|December 29, 2025
Postoperative course and safety profile of the suture scaffold technique in breast-conserving surgery: a single-institution observational studyReiko Mitsueda, Yasuyo Ohi, Yukari Mochitomi, et al.
The Oncologist|December 15, 2020
Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast CancerYasuaki Sagara, Masanori Mori, Sena Yamamoto, et al.
Breast Cancer (Tokyo, Japan)|October 19, 2021
Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of JapanDaisuke Yotsumoto, Yasuaki Sagara, Hiraku Kumamaru, et al.
The Lancet. Oncology|May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studyKenji Tamura, Junji Tsurutani, Shunji Takahashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2020
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib StudyShanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2020
Reply to T.J.A. DekkerShanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Breast Cancer (Tokyo, Japan)|January 31, 2026
Efficacy and prognostic predictors of primary systemic therapy for de novo Stage IV breast cancer. Exploratory analysis of JCOG1017 PRIM-BCTadahiko Shien, Makoto Ishitobi, Keita Sasaki, et al.
Trials|May 9, 2020
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, et al.
Pageof 14